• Adnan Yalçın Demirci, Yahya Güvenç, Ersin Özeren, Çetin Akyol, Pınar Bayram, Deniz Billur, Sevim Aydın, Hakan Seçkin, and Kazim Yiğitkanlı.
• Department of Neurosurgery, Yüksek İhtisas Education and Training Hospital, Bursa, Turkey.
• Turk J Med Sci. 2021 Oct 1; 51 (5): 269827042698-2704.

BackgroundThis study investigated the effect of vascular endothelial growth factor (VEGF) inhibitor bevacuzimab (BVZ) on the rabbit basilar artery using an experimental subarachnoid hemorrhage (SAH) model.MethodsEighteen adult male New-Zealand white rabbits were randomly divided into three groups: a control group (n = 6), SAH group (n = 6), and SAH+BVZ group (n = 6). Experimental SAH was created by injecting autologous arterial blood into the cisterna magna. In the treatment group, the subjects were administered a daily dose of 10 mg/kg, intravenous BVZ for 2 days after the SAH. Basilar artery diameters were measured with magnetic resonance angiography (MRA) 72 h after the SAH in all groups. After 72 h, whole brains, including the upper cervical region, were obtained from all the animals after perfusion and fixation of the animal. The wall thickness, luminal area, and the apoptosis at the basilar arteries were evaluated in all groups.ResultsBVZ significantly prevented SAH-induced vasospasm confirmed in vivo with MRA imaging with additional suppression of apoptosis on basilar artery wall.DiscussionVEGF inhibition with BVZ has shown to have a vasospasm and apoptosis attenuating effect on basilar artery in a SAH model.

19 keywords...

hide…